What are the diagnostic criteria for hepatorenal syndrome in a cirrhotic patient with ascites who develops acute kidney injury?

Diagnosis of Hepatorenal Syndrome (HRS-AKI)

HRS-AKI is diagnosed when a cirrhotic patient with ascites develops AKI that fails to respond to 2 consecutive days of diuretic withdrawal and albumin volume expansion (1 g/kg/day, maximum 100 g/day), in the absence of shock, nephrotoxic drugs, or structural kidney injury. 1

Diagnostic Criteria for HRS-AKI

The International Club of Ascites (ICA) 2015 revised criteria represent the current gold standard 2, 1:

Required Elements:

1. Cirrhosis with ascites - Both must be present

2. AKI according to ICA-AKI criteria:

   • Increase in serum creatinine ≥0.3 mg/dL within 48 hours, OR
   • Increase in serum creatinine ≥50% from baseline within 7 days 1

3. Failed therapeutic trial:

   • No response after 2 consecutive days of:
     • Diuretic withdrawal
     • Volume expansion with albumin 1 g/kg bodyweight/day (maximum 100 g/day) 1

4. Absence of shock - Excludes septic or cardiogenic causes

5. No nephrotoxic drug exposure:

   • No current or recent NSAIDs
   • No aminoglycosides
   • No iodinated contrast media 1

6. No structural kidney injury:

   • Proteinuria <500 mg/day
   • Microhematuria <50 RBCs per high-power field
   • Normal renal ultrasonography 1

Critical Diagnostic Updates

The 2015 ICA criteria eliminated the old requirement for serum creatinine >2.5 mg/dL, allowing earlier diagnosis and treatment initiation. 1 This change was driven by evidence showing that higher creatinine at treatment initiation correlates with lower response rates to vasoconstrictors.

HRS-AKI is no longer purely a diagnosis of exclusion - recent evidence suggests it can coexist with other AKI phenotypes like acute tubular necrosis. 3 However, the diagnostic criteria still require excluding other obvious causes.

Staging of AKI in Cirrhosis

Once AKI is identified, stage it according to ICA-AKI criteria 4, 5:

• Stage 1: sCr increase ≥0.3 mg/dL or 1.5-2× baseline
• Stage 2: sCr increase >2-3× baseline
• Stage 3: sCr increase >3× baseline OR sCr ≥4.0 mg/dL with acute increase ≥0.3 mg/dL OR initiation of renal replacement therapy

Diagnostic Algorithm

For Stage 1 AKI 2, 1:

1. Immediately review and withdraw diuretics, nephrotoxic drugs, vasodilators, NSAIDs
2. Expand plasma volume if hypovolemia suspected (crystalloids, albumin, or blood)
3. Treat infections promptly (albumin mandatory for SBP per guidelines)
4. Monitor closely - if progression occurs, treat as Stage 2/3

For Stage 2 or 3 AKI (or Stage 1 with progression) 2:

1. Withdraw diuretics if not already done
2. Administer IV albumin 1 g/kg/day × 2 days (maximum 100 g/day)
3. After 48 hours, reassess:
   • If improved: Continue monitoring, not HRS-AKI
   • If no response AND meets all other criteria: Diagnose HRS-AKI and initiate vasoconstrictors 2, 1

Important Caveats

Baseline creatinine determination is critical 1: Use a stable creatinine value from the previous 3 months when available. If multiple values exist, use the one closest to admission. If no prior value exists, use admission creatinine as baseline.

The 48-hour albumin trial remains standard 6, despite recent debate. New evidence shows significant responses occur between 24-48 hours, supporting the traditional 2-day approach rather than abbreviated protocols.

Structural kidney damage may still exist 1: The criteria exclude macroscopic signs of structural injury, but tubular damage can coexist. Urinary biomarkers (NGAL, KIM-1, IL-18) show promise for differentiating HRS-AKI from acute tubular necrosis but require further validation.

Volume overload risk 4, 7: Fixed albumin dosing can cause pulmonary edema, especially in patients with cirrhotic cardiomyopathy or diastolic dysfunction. Monitor carefully for respiratory complications, particularly in critically ill patients with ACLF-3.

Most experts recommend against vasoconstrictors for Stage 1 AKI with sCr <1.5 mg/dL 2 due to concerns about premature treatment, though this remains an area without consensus.